Alvotech, a prominent Iceland-based biotech company specializing in biosimilars, experienced a significant financial upswing in the first half of 2025, transitioning from a substantial loss to a notable net profit. This transformation was primarily fueled by the exceptional commercial performance of its key biosimilar products, leading to over a 200% year-on-year surge in product revenues. The company achieved its first-ever quarterly positive cash flow from operations, indicating a robust financial position.
During the initial six months of 2025, Alvotech reported a remarkable net profit of $141.7 million, a stark contrast to the $153.5 million net loss recorded in the same period in 2024. The total revenue for this period stood at $306 million, marking a substantial 30% increase from the previous year. This growth was predominantly attributed to a significant rise in product revenue, soaring to $204.7 million from $65.9 million in the corresponding period.
Alvotech’s Chairman and CEO, Robert Wessman, emphasized the company’s positive momentum, highlighting the confirmation of their business trajectory and the promising opportunities ahead. The bolstered financial performance was backed by new and expanded partnerships, underscoring Alvotech’s increased development initiatives. As of June 30, 2025, the company held cash and cash equivalents amounting to $151.5 million, further solidifying its operational strength.
The success of Alvotech was primarily propelled by the market expansion of its two approved biosimilars: a high-concentration adalimumab (Humira) biosimilar and an ustekinumab (Stelara) biosimilar. The adalimumab biosimilar, marketed as Simlandi in the US and Hukyndra in Europe, continued to demonstrate robust sales performance, especially after securing FDA approval as the first high-concentration, citrate-free interchangeable biosimilar to Humira in February 2024. On the other hand, the ustekinumab biosimilar, known as Selarsdi in the US and Uzpruvo in Europe, significantly contributed to the revenue surge following its interchangeable status approval by the FDA in April 2025.
Apart from its current product portfolio, Alvotech maintains a pipeline of biosimilar candidates targeting various therapeutic areas such as autoimmune disorders, eye conditions, and oncology. The company witnessed progress in several programs during the year, with some transitioning out of the clinical phase. Notably, Alvotech’s biologics license applications for proposed biosimilars to Prolia/Xgeva (denosumab) and Eylea (aflibercept) were accepted by the FDA. The approval of the aflibercept biosimilar, now named Mynzepli, in Europe marked a significant milestone towards commercialization.
In a strategic move to enhance its research and development capabilities, Alvotech acquired Xbrane Biopharma’s research and development operations in Sweden in March 2025, including a biosimilar candidate to Cimzia (certolizumab pegol), now designated as AVT10. This acquisition, valued at SEK 275 million (approximately $28.9 million), aligns with the company’s ambition to establish itself as a global leader in the biosimilar domain.
- Alvotech achieved a remarkable financial turnaround in the first half of 2025, transitioning from a significant loss to a substantial net profit driven by strong biosimilar sales.
- The company reported a notable increase of over 200% in product revenues year-on-year, leading to its first-ever quarterly positive cash flow from operations.
- Market expansion of its key biosimilars, including high-concentration adalimumab and ustekinumab biosimilars, significantly contributed to Alvotech’s revenue surge, alongside strategic partnerships and pipeline advancements.
- Alvotech’s acquisition of Xbrane Biopharma’s research and development operations in Sweden further strengthens its research capabilities and underscores its commitment to becoming a global leader in the biosimilar space.
Tags: biosimilars, biopharma, biotech, regulatory
Read more on centerforbiosimilars.com